Concepedia

Keith Dillman

KD

Statistics

Publications

11

Citations

832

H-Index

11

Active since

2001

Affiliations

AstraZeneca (United States)(Current)

Pfizer (United States)

AstraZeneca (United Kingdom)

AstraZeneca (Sweden)

Keith Dillman is an author at AstraZeneca (United States) specializing in drug discovery, medicinal chemistry, and pharmacology.

Publications per year

2001–2024

11

Publications

11

AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia

Erika Krasnickas Keeton, Kristen McEachern, Keith Dillman et al. · Blood · 2013 · 247 citations

, , +11

Mechanism for the allosteric regulation of phosphodiesterase 2A deduced from the X-ray structure of a near full-length construct

Jayvardhan Pandit, Michael D. Forman, Kimberly F. Fennell et al. · Proceedings of the National Academy of Sciences · 2009 · 162 citations · Full text

, , +17

cAMP-Dependent Protein Kinase Mediates Activity-Regulated Synaptic Targeting of NMDA Receptors

F. Thomas Crump, Keith Dillman, Ann Marie Craig · Journal of Neuroscience · 2001 · 139 citations · Full text

, , +17

Structural basis for the catalytic mechanism of human phosphodiesterase 9

Shenping Liu, Mahmoud N. Mansour, Keith Dillman et al. · Proceedings of the National Academy of Sciences · 2008 · 70 citations · Full text

, , +17

Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88<sup>L265P</sup> Diffuse Large B-Cell Lymphoma

James S. Scott, Sébastien L. Degorce, Rana Anjum et al. · Journal of Medicinal Chemistry · 2017 · 56 citations · Full text

, , +10

1–5 of 11